Pomaglumetad methionil (
LY2140023 monohydrate, hereafter referred to as
LY2140023) is currently in clinical development as a potential new treatment for
schizophrenia. If found to be effective,
LY2140023 would represent a novel non-dopaminergic based
therapy for this disorder that may restore balance to the
glutamate dysregulation hypothesized to underlie
schizophrenia. This article presents available clinical trial data that describe the safety, tolerability, and efficacy of
LY2140023 in patients with
schizophrenia. Data indicate that this compound appears to have an efficacy profile consistent with currently available
antipsychotic drugs, although confirmation of its efficacy awaits further clinical testing.
LY2140023 is generally well tolerated and appears to have a low association with adverse events related to
dopamine D2 receptor antagonism and with
weight gain, which are commonly seen with current
antipsychotics. A potential association of
LY2140023 treatment and seizure events has been identified, although an accurate and reliable understanding of the incidence of these events requires further clinical testing, which is underway. Evaluation of the safety, tolerability, and efficacy of
LY2140023 is continuing. This article is part of a Special Issue entitled '
Metabotropic Glutamate Receptors'.